Therapeutic or Preventive Procedure
Lava cuts jobs by 30% after key drug discontinued
LAVA Therapeutics, restructuring, workforce reduction, LAVA-1207, discontinuation, mCRPC, LAVA-1266, strategic alternatives, cash runway
Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss
Regeneron Pharmaceuticals, DB-OTO gene therapy, otoferlin (OTOF) gene, congenital hearing loss, intracochlear injection
Pfizer Discontinues Hemophilia B Gene Therapy Beqvez, Exits Gene Therapy Field
Pfizer, Beqvez, hemophilia B, gene therapy, discontinuation, portfolio exit
Entrada given go-ahead to test DMD therapy after two-year hold
Entrada, Muscular Dystrophy, Duchenne, DMD, United States Food and Drug Administration, Adult, Exons
Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations
Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials
FDA Lifts Clinical Hold on Entrada’s Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years
Duchenne muscular dystrophy, ENTR-601-44, Entrada Therapeutics, FDA, clinical hold, exon 44 skipping, ELEVATE-44-102, Phase 1b trial
Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation
Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry
CDC Vaccine Advisory Committee Meeting Postponed Following RFK Jr.’s Confirmation as HHS Secretary
ACIP, CDC, vaccine recommendations, Robert F. Kennedy Jr., HHS, postponement, public health, immunization policy
Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery
Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics